Deerfield Management Company, L.P. (Series C) Nuvation Bio Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $3.69 $676,488 - $967,536	262,205 New	262,205 $765,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $9.42 Million - $14 Million	5,609,500 Added 2286.23%	5,854,860 $11.2 Million
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $71,154 - $991,254	245,360 New	245,360 $550,000
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $11.6 Million - $20.9 Million	-3,577,233 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $5.32 Million - $8.36 Million	577,233 Added 19.24%	3,577,233 $33.3 Million
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $27 Million - $43.7 Million	3,000,000 New	3,000,000 $31.4 Million

Others Institutions Holding NUVB

# of Institutions

158

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

Decheng Capital LLC Menlo Park, CA

26M
Shares

$73.2 Million
14.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

19.2M
Shares

$54.2 Million
1.92% of portfolio
Black Rock Inc. New York, NY

16.2M
Shares

$45.8 Million
0.0% of portfolio
Omega Fund Management, LLC Boston, MA

13.1M
Shares

$36.9 Million
44.61% of portfolio
Octagon Capital Advisors LP New York, NY

12.2M
Shares

$34.3 Million
6.76% of portfolio

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account